What's Next For Clovis Oncology?

Wellington Management Group LLP now owns 1,331,669 shares of the biopharmaceutical company's stock worth $84,788,000 after buying an additional 1,318,669 shares during the period.

Overall, one research analyst has assigned a Hold rating and 7 research analysts have given a Buy rating to the stock. Clovis Oncology itself will be offering all shares of the common stock.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. The original version of this story can be accessed at https://sportsperspectives.com/2017/06/19/nicholas-investment-partners-lp-purchases-shares-of-27864-clovis-oncology-inc-clvs.html. Blackrock Grp invested in 20,918 shares. Clovis Oncology is headquartered in Boulder, Colorado and has additional offices in San Francisco, California and Cambridge, United Kingdom. Stifel has 13,017 shares for 0% of their portfolio. Healthcor Mngmt Limited Partnership holds 1.57% of its portfolio in Clovis Oncology Inc (NASDAQ:CLVS) for 625,000 shares.

A number of other large investors have also added to or reduced their stakes in the stock. (NASDAQ:CLVS) traded up 45.71% during mid-day trading on Monday, reaching $87.38. The company's 50 day moving average is $54.46 and its 200-day moving average is $55.14. D E Shaw & Com Inc has invested 0.05% in Clovis Oncology Inc (NASDAQ:CLVS).

In afternoon trading on the stock market today, Clovis stock flew 49.4% near 89.93, after earlier hitting a 91 high last seen in November.

Clovis Oncology (NASDAQ:CLVS) last released its quarterly earnings data on Wednesday, May 3rd. They expect $-1.37 EPS, up 33.82 % or $0.70 from last year's $-2.07 per share. The business had revenue of $7.05 million for the quarter, compared to analysts' expectations of $6.04 million. Clovis Oncology, Inc. The firm's market cap is $2.68 billion.

WARNING: This report was posted by Markets Daily and is the property of of Markets Daily. If you are accessing this article on another domain, it was illegally stolen and republished in violation of United States and global trademark and copyright laws. Principal Inc accumulated 5,898 shares or 0% of the stock. Now Clovis Oncology, Inc.'s current price is $28.03 shy of the official highest sell-side analyst price target on Wall Street.

Clovis Oncology Inc. said on Monday it plans to launch a $250 million stock offering. Finally, Zacks Investment Research upgraded shares of Clovis Oncology from a "hold" rating to a "buy" rating and set a $68.00 target price for the company in a research report on Tuesday, February 7th. Jpmorgan Chase And Co reported 170,388 shares. The company presently has a consensus rating of "Buy" and a consensus price target of $66.87. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating, eight have given a buy rating and one has given a strong buy rating to the stock. The company now has an average rating of "Buy" and an average target price of $63.33.

In other Clovis Oncology news, insider Gillian C. Ivers-Read sold 3,000 shares of the stock in a transaction on Monday, April 17th.

About 820,789 shares traded or 9.10% up from the average. Teachers Advisors LLC now owns 420,512 shares of the biopharmaceutical company's stock worth $18,679,000 after buying an additional 254,898 shares in the last quarter. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 17.40% of the company's stock.

Clovis Oncology, Inc.is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the U.S., Europe and additional global markets.

  • Zachary Reyes